Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (961-970 of 993) with videos related to

Pageof 100
Sort By:
Cancer|December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trialsGeorges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
Future Oncology (London, England)|June 19, 2026
Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadirMichael Ong, Christopher Morash, Robert J Hamilton, et al.
Plos Medicine|August 16, 2020
Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validationAndrée-Anne Grosset, Frédérick Dallaire, Tien Nguyen, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 21, 2024
Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forumFred Saad, Sebastien J Hotte, Krista Noonan, et al.
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
Journal of Biomedical Optics|November 7, 2021
Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimensArthur Plante, Frédérick Dallaire, Andrée-Anne Grosset, et al.
The New England Journal of Medicine|February 18, 2022
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate CancerMatthew R Smith, Maha Hussain, Fred Saad, et al.
The Lancet. Oncology|December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trialKarim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 25, 2016
Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional studyLibni J Eapen, Edward Jones, Wassim Kassouf, et al.
Nature Communications|May 7, 2026
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trialPadmanee Sharma, Michael Krainer, Fred Saad, et al.
Pageof 100

Showing results (961-970 of 993) with videos related to

Sort By:
Pageof 100
Cancer|December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trialsGeorges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
Future Oncology (London, England)|June 19, 2026
Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadirMichael Ong, Christopher Morash, Robert J Hamilton, et al.
Plos Medicine|August 16, 2020
Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validationAndrée-Anne Grosset, Frédérick Dallaire, Tien Nguyen, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 21, 2024
Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forumFred Saad, Sebastien J Hotte, Krista Noonan, et al.
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
Journal of Biomedical Optics|November 7, 2021
Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimensArthur Plante, Frédérick Dallaire, Andrée-Anne Grosset, et al.
The New England Journal of Medicine|February 18, 2022
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate CancerMatthew R Smith, Maha Hussain, Fred Saad, et al.
The Lancet. Oncology|December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trialKarim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 25, 2016
Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional studyLibni J Eapen, Edward Jones, Wassim Kassouf, et al.
Nature Communications|May 7, 2026
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trialPadmanee Sharma, Michael Krainer, Fred Saad, et al.
Pageof 100